PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33751333-4	2021	The topical treatment with the novel TRPV1 antagonist, diosmetin (1%; 15 mg/ear), reduced ear oedema, MPO activity, and MIP-2 and IL-1beta cytokines levels by 82 +- 8%, 59 +- 10%, 40 +- 12%, and 85 +- 9%, respectively.	diosmetin	55-64	myeloperoxidase	Mus musculus	102-105	
28365974-7	2018	Additionally, increased MPO, MDA and ROS levels induced by LPS were also markly suppressed by diosmetin.	diosmetin	94-103	myeloperoxidase	Mus musculus	24-27	
24966921-6	2014	Pretreatment with diosmetin significantly reduced serum levels of amylase and lipase; the histological injury; the secretion of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6; myeloperoxidase (MPO) activity, trypsinogen activation peptide (TAP) level, the expression of inducible nitric oxide synthase (iNOS); and the nuclear factor (NF)-kappaB activation in cerulein-induced AP.	diosmetin	18-27	myeloperoxidase	Mus musculus	214-217	
24966921-6	2014	Pretreatment with diosmetin significantly reduced serum levels of amylase and lipase; the histological injury; the secretion of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6; myeloperoxidase (MPO) activity, trypsinogen activation peptide (TAP) level, the expression of inducible nitric oxide synthase (iNOS); and the nuclear factor (NF)-kappaB activation in cerulein-induced AP.	diosmetin	18-27	myeloperoxidase	Mus musculus	197-212